Anti-pd-l1 antibodies and uses thereof
AssigneeMerck Patent GmbH
InventorsHoracio G. Nastri, Christel Iffland, Olivier Leger, Qi An, Mark Cartwright, Sean D. McKenna
Life of this patent
Estimating the term…
Abstract
The present application relates to anti-PD-L1 antibodies or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, for the treatment of and cancer.
Claims28
1-75. (canceled)
A method of treating cancer comprising administering to a subject in need thereof an effective amount of an anti-PD-L1 antibody which induces antibody dependent cell-mediated cytotoxicity (ADCC).
77-92. (canceled)
Dependencies are inferred from the claim text.